Bydureon grew 37% in H1 2015 !!

Byetta also up 4% for a combined sales of $435 million.

Farxiga sales were $205 million.

Onglyza $391 million down $2million.

Seems like the Diabetes portfolio is doing pretty well with over 1 billion in H1, but injectable gets short shrift from company.

 

oops failed to type that Bydureon sales were $263 million.

 

Topher strategy is working. Stop complaining. How were Farxiga sales compared to projections

 

I totally agree. Looks like the plan to split the products has worked. Great job AZ. Just go to work and let the management team do their job

 

That only makes us about 8 billion in the hole from the hole buyout thing. Amylin and BMS

 

You have to admit the plan to switch the sales forces is working. Give Paul credit

 

No reason for Byetta to be ahead of Bydureon by that much three years after launch.

 

admit it. Splitting the salesforce made sense. Look at how well the diabetes portfolio did for the quarter. Watch out Victoza, Januvia, And Invokana. We have the best management team in the industry

 

Topher has achieved God like status! Way to go BIG T! Way to go! Lead on!

 

You are the same Ass-wipe responding to your own posts ! We are in big trouble the entire experiment is a failure , Diabetes is falling down a dark hole its just a matter of time .

 

The tv ad campaign is at least $300,000,000.00. Sales reps are equal that. Cost of goods is virtually $0.

Maybe it will work.

 

Bydureon 230 million in worldwide sales
Byetta 205 million

 

Quit posting Gopher. Your plan sucks!!

 

Read the Q2 report very carefully. Lots of "hidden" meanings. Q1 payouts were less due to National number. We underperformed. Q2 is an unknown based on national multiplier. It's like Obama telling us the economy is strong and we continue to grow. Smoke and mirrors. The hour and forty five minute earning report is online if your truly interested in "how well we are doing"

 

if you would stop posting and go to work ,the plan would work. It was well thought out and what the salesforce wanted. Go to work. My numbers look fine and I am selling Bydureon . You just have to find those 10 docs to put you on the map instead you post on cafe pharma the plan makes sense to split the sales forces. Just go to work and watch the numbers fly. AZ takes care of those who bring in the sales numbers

 

I am doing extremely well. I'm a stockholder first and employee second. This model is not cost effective nor does it "put patients first". I look at things from a big picture perspective, not the "I" mentality. Everybody has different things that motivate them. Congrats on your growth. Let me know when you hit a 40 share, then will compare notes.

 

Topher, we are behind you and have confidence in you! Don't listen to all the negativity! Both Bye's are doing great! Don't change a damn thing you are doing, because I can tell you, there are a LOT more behind you than against you!!!!!!!

 

Yes Topher. Tell us how well we are doing nationally with Nrx and nbrx with our portfolio? Tell us why the ESS team is selling BYD first on every call? Why did we add primary care to Farxiga? Yes we are behind you. Hoping not to be in front.

 

1:

None of you is selling anything on any call. You are showing up and that is enough to pressure the doctors to RX.

2:

I am the big shot here.

 

People aren't very bright. Look at q1-q4 2014. Diabetes grew 139%. Now at 37% for 2015. Did we slow the train? It's simple math.